Dogwood Announces FDA Acceptance of SP16 IND Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Should l Buy DWTX?
Dogwood announced FDA acceptance of an investigational new drug application for its development candidate SP16, administered intravenously, for the treatment of chemotherapy-induced pain and peripheral neuropathy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DWTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DWTX
Wall Street analysts forecast DWTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.700
Low
12.00
Averages
21.00
High
30.00
Current: 1.700
Low
12.00
Averages
21.00
High
30.00
About DWTX
Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dogwood Therapeutics to Report Q1 2026 Financial Results on May 14
- Earnings Announcement: Dogwood Therapeutics is set to release its Q1 2026 financial results on May 14, 2026, before market open, which is expected to provide investors with insights into the company's operational and financial health.
- R&D Progress: The company is advancing its lead product candidate, Halneuron®, currently in Phase 2b trials aimed at treating chemotherapy-induced neuropathic pain, having received Fast Track designation from the FDA, indicating its potential in pain management.
- New Drug Candidate: SP16 IV, an LRP1 agonist, is fully funded for its upcoming Phase 1b trial by the National Cancer Institute, highlighting the company's innovative efforts in neuropathy treatment and nerve damage repair post-chemotherapy.
- Shareholder Background: Dogwood's largest shareholder is a member of CK Life Sciences Int'l., listed in Hong Kong, reflecting the company's influence in international capital markets and potential strategic partnership opportunities.
See More
Dogwood Secures SP16 License for Cancer Pain Treatment
- FDA IND Approval: Dogwood Therapeutics announced that its IND application for SP16 has been accepted by the FDA, marking a significant step in the development of non-opioid drugs for treating chemotherapy-induced pain and neuropathy, which is expected to enhance the diversity and competitiveness of its product pipeline.
- Clinical Trial Funding: The Phase 1b trial for SP16 will be fully funded by a $2.5 million grant from the National Cancer Institute, with patient enrollment anticipated to begin in mid-2026, providing essential financial support for advancing clinical development.
- Market Demand Potential: Chemotherapy-induced peripheral neuropathy affects approximately 30-40% of patients and can persist long-term, making the development of SP16 not only a response to this market need but also a potential improvement in the quality of life for cancer survivors, highlighting its significant social value.
- Strategic Partnership: Dogwood's collaboration with Serpin Pharma grants it a global license for SP16, further solidifying its market position in cancer pain management and laying the groundwork for future commercialization efforts.
See More
Virios Therapeutics Q4 Financial Overview
- Earnings Performance: Virios Therapeutics reported a GAAP EPS of -$0.26 for Q4 2025, indicating ongoing challenges in profitability that may affect investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, Dogwood Therapeutics had cash and cash equivalents totaling $6.5 million, highlighting liquidity pressures that could limit future R&D investments and operational flexibility.
- Stable R&D Expenses: Research and development expenses for Q4 2025 remained flat at $2.3 million compared to Q4 2024, suggesting a consistent commitment to R&D, yet failing to drive financial improvement or innovation breakthroughs.
- Market Attention: Virios Therapeutics' financial information and historical earnings data have garnered attention from Seeking Alpha's Quant Rating, reflecting heightened market scrutiny regarding the company's future performance and potential stock volatility.
See More
Dogwood Therapeutics Achieves Milestone in HALT-CINP Trial
- Significant Trial Progress: Dogwood Therapeutics has achieved over 50% enrollment in the HALT-CINP Phase 2b trial, with an early termination rate of only 4.3% among 116 patients, indicating good tolerability, and top-line results are expected in Q3 2026.
- Preliminary Clinical Efficacy: An interim analysis of 97 patients showed that Halneuron® treated patients demonstrated significant pain improvement compared to placebo, as confirmed by an independent statistical review committee, highlighting the drug's potential in treating chemotherapy-induced neuropathic pain.
- Statistical Power Assurance: The study is designed to provide over 80% statistical power to detect treatment differences between Halneuron® and placebo upon unblinding in Q3 2026, which could fill the current market gap for approved therapies if successful.
- Future Development Outlook: As a non-opioid NaV1.7 analgesic, Halneuron® has received FDA fast track designation, potentially offering new treatment options for millions of chemotherapy patients and addressing the urgent market need for effective therapies.
See More
Dogwood Therapeutics Raises $12.5 Million to Advance Halneuron® Development
- Funding Amount: Dogwood Therapeutics successfully raised approximately $12.5 million through a registered direct offering and concurrent private placement, which is expected to be utilized for advancing the clinical development of Halneuron®, thereby enhancing the company's innovation in non-opioid medications.
- Equity Structure: The financing involves the issuance of 4,386,037 shares of common stock and corresponding warrants at a price of $2.85 per share, reflecting market recognition of the company's research potential and potentially boosting investor confidence.
- Strategic Use: The company plans to use the net proceeds from the offering to support the Phase 2b clinical trial of Halneuron® while also pursuing strategic opportunities to strengthen its research portfolio, aiming to improve care standards for patients suffering from chemotherapy-induced pain and neuropathy.
- Market Outlook: This financing not only provides Dogwood with additional capital support but also lays the groundwork for future Phase 3 clinical development, further solidifying its market position in the biopharmaceutical industry.
See More
Dogwood Therapeutics Reports Positive Interim Results for Halneuron in Chemotherapy-Induced Neuropathic Pain
- Clinical Trial Progress: Dogwood Therapeutics' Phase 2b trial for chemotherapy-induced neuropathic pain shows that 97 patients experienced significant pain improvement over four weeks, with a dropout rate of only 4.4%, indicating the potential of Halneuron as a viable treatment option.
- Market Need: With no FDA-approved treatments for moderate-to-severe chemotherapy-induced neuropathic pain, Halneuron's success could address a significant unmet medical need for cancer survivors suffering from this debilitating condition.
- Financial Challenges: Despite the encouraging clinical data, Dogwood's stock plummeted nearly 24% due to concerns over its limited cash reserves of $10.1 million, which only provide operational runway through the first quarter of 2026, raising investor apprehensions.
- Future Outlook: The company expects to release top-line results in the third quarter of 2026, and if successful, this could represent the first statistically significant study under FDA chronic pain guidance, potentially paving the way for a Phase 3 registration program.
See More
Dogwood Therapeutics to Report Q1 2026 Financial Results on May 14
- Earnings Announcement: Dogwood Therapeutics is set to release its Q1 2026 financial results on May 14, 2026, before market open, which is expected to provide investors with insights into the company's operational and financial health.
- R&D Progress: The company is advancing its lead product candidate, Halneuron®, currently in Phase 2b trials aimed at treating chemotherapy-induced neuropathic pain, having received Fast Track designation from the FDA, indicating its potential in pain management.
- New Drug Candidate: SP16 IV, an LRP1 agonist, is fully funded for its upcoming Phase 1b trial by the National Cancer Institute, highlighting the company's innovative efforts in neuropathy treatment and nerve damage repair post-chemotherapy.
- Shareholder Background: Dogwood's largest shareholder is a member of CK Life Sciences Int'l., listed in Hong Kong, reflecting the company's influence in international capital markets and potential strategic partnership opportunities.
See More
Dogwood Secures SP16 License for Cancer Pain Treatment
- FDA IND Approval: Dogwood Therapeutics announced that its IND application for SP16 has been accepted by the FDA, marking a significant step in the development of non-opioid drugs for treating chemotherapy-induced pain and neuropathy, which is expected to enhance the diversity and competitiveness of its product pipeline.
- Clinical Trial Funding: The Phase 1b trial for SP16 will be fully funded by a $2.5 million grant from the National Cancer Institute, with patient enrollment anticipated to begin in mid-2026, providing essential financial support for advancing clinical development.
- Market Demand Potential: Chemotherapy-induced peripheral neuropathy affects approximately 30-40% of patients and can persist long-term, making the development of SP16 not only a response to this market need but also a potential improvement in the quality of life for cancer survivors, highlighting its significant social value.
- Strategic Partnership: Dogwood's collaboration with Serpin Pharma grants it a global license for SP16, further solidifying its market position in cancer pain management and laying the groundwork for future commercialization efforts.
See More
Virios Therapeutics Q4 Financial Overview
- Earnings Performance: Virios Therapeutics reported a GAAP EPS of -$0.26 for Q4 2025, indicating ongoing challenges in profitability that may affect investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, Dogwood Therapeutics had cash and cash equivalents totaling $6.5 million, highlighting liquidity pressures that could limit future R&D investments and operational flexibility.
- Stable R&D Expenses: Research and development expenses for Q4 2025 remained flat at $2.3 million compared to Q4 2024, suggesting a consistent commitment to R&D, yet failing to drive financial improvement or innovation breakthroughs.
- Market Attention: Virios Therapeutics' financial information and historical earnings data have garnered attention from Seeking Alpha's Quant Rating, reflecting heightened market scrutiny regarding the company's future performance and potential stock volatility.
See More
Dogwood Therapeutics Achieves Milestone in HALT-CINP Trial
- Significant Trial Progress: Dogwood Therapeutics has achieved over 50% enrollment in the HALT-CINP Phase 2b trial, with an early termination rate of only 4.3% among 116 patients, indicating good tolerability, and top-line results are expected in Q3 2026.
- Preliminary Clinical Efficacy: An interim analysis of 97 patients showed that Halneuron® treated patients demonstrated significant pain improvement compared to placebo, as confirmed by an independent statistical review committee, highlighting the drug's potential in treating chemotherapy-induced neuropathic pain.
- Statistical Power Assurance: The study is designed to provide over 80% statistical power to detect treatment differences between Halneuron® and placebo upon unblinding in Q3 2026, which could fill the current market gap for approved therapies if successful.
- Future Development Outlook: As a non-opioid NaV1.7 analgesic, Halneuron® has received FDA fast track designation, potentially offering new treatment options for millions of chemotherapy patients and addressing the urgent market need for effective therapies.
See More
Dogwood Therapeutics Raises $12.5 Million to Advance Halneuron® Development
- Funding Amount: Dogwood Therapeutics successfully raised approximately $12.5 million through a registered direct offering and concurrent private placement, which is expected to be utilized for advancing the clinical development of Halneuron®, thereby enhancing the company's innovation in non-opioid medications.
- Equity Structure: The financing involves the issuance of 4,386,037 shares of common stock and corresponding warrants at a price of $2.85 per share, reflecting market recognition of the company's research potential and potentially boosting investor confidence.
- Strategic Use: The company plans to use the net proceeds from the offering to support the Phase 2b clinical trial of Halneuron® while also pursuing strategic opportunities to strengthen its research portfolio, aiming to improve care standards for patients suffering from chemotherapy-induced pain and neuropathy.
- Market Outlook: This financing not only provides Dogwood with additional capital support but also lays the groundwork for future Phase 3 clinical development, further solidifying its market position in the biopharmaceutical industry.
See More
Dogwood Therapeutics Reports Positive Interim Results for Halneuron in Chemotherapy-Induced Neuropathic Pain
- Clinical Trial Progress: Dogwood Therapeutics' Phase 2b trial for chemotherapy-induced neuropathic pain shows that 97 patients experienced significant pain improvement over four weeks, with a dropout rate of only 4.4%, indicating the potential of Halneuron as a viable treatment option.
- Market Need: With no FDA-approved treatments for moderate-to-severe chemotherapy-induced neuropathic pain, Halneuron's success could address a significant unmet medical need for cancer survivors suffering from this debilitating condition.
- Financial Challenges: Despite the encouraging clinical data, Dogwood's stock plummeted nearly 24% due to concerns over its limited cash reserves of $10.1 million, which only provide operational runway through the first quarter of 2026, raising investor apprehensions.
- Future Outlook: The company expects to release top-line results in the third quarter of 2026, and if successful, this could represent the first statistically significant study under FDA chronic pain guidance, potentially paving the way for a Phase 3 registration program.
See More
